EB
Engine Biosciences
CA - Redwood City
Biotechnology1 H-1B visas (FY2023)Focus: AI & genomics
Engine Biosciences is a life sciences company focused on AI & genomics.
NeurologyInfectious DiseasesCardiovascularOncologyNephrology
Open Jobs
1
Products & Portfolio (23)
7 discontinued products not shown
ALTAFLUOR BENOX
fluorescein sodium and benoxinate hydrochloride
Peak
OPHTHALMIC · SOLUTION/DROPS
12. CLINICAL PHARMACOLOGY This product is the combination of a disclosing agent with a rapidly acting ester anesthetic of short duration. 12. 2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.
2017
30
ANASTROZOLE
anastrozole tablets
Post-LOE
ORAL · TABLET
Aromatase Inhibitors
advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapybreast cancer
2018
30
BACLOFEN
baclofen
Post-LOE
ORAL · TABLET
GABA A Agonists
the treatment of skeletal muscle spasm resulting from rheumatic disordersmultiple sclerosisParkinson's disease
1996
30
CIPROFLOXACIN HYDROCHLORIDE
ciprofloxacin hydrochloride
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY Systemic Absorption: A systemic absorption study was performed in which Ciprofloxacin Ophthalmic Solution, USP 0.3% was administered in each eye every two hours while awake for two days followed by every four hours while awake for an additional 5 days. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL. The mean concentration was usually less than 2.5 ng/mL. Microbiology: Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive organisms. The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase which is needed for the synthesis of bacterial DNA. Ciprofloxacin has been shown to be active against most strains of the following organisms both in vitro and in clinical infections [See section]: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus ( Viridans Group ) Gram-Negative: Haemophilus influenzae Pseudomonas aeruginosa Serratia marcescens Ciprofloxacin has been shown to be active in vitro against most strains of the following organisms, however, the clinical significance of these data is unknown: Gram-Positive: Enterococcus faecalis (Many strains are only moderately susceptible) Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus saprophyticus Streptococcus pyogenes Gram-Negative: A cinetobacter calcoaceticus subsp . anitratus Aeromonas caviae Aeromonas hydrophila Brucella melitensis Campylobacter coli Campylobacter jejuni Citrobacter diversus Citrobacter freundii Edwardsiella tarda Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus duc reyi Haemophilus parainfluenzae Klebsiella pneumonia Klebsiella oxytoca Legionella pneumophila Moraxella (Branhamella ) catarrhalis Morganella morganii Neisseria gonorrho eae Neisseria meningitidi s Pasteurella multocida Proteus mirabilis Proteus vulgaris Providencia rettgeri Providencia stuartii Salmonella enteritidis Salmonella typhi Shigella sonneii Shigella flexneri Vibrio chole rae Vibrio parahaemolyticus Vibrio vulnificus Yersinia enterocolitica Other Organisms: Chlamydia trachomatis (only moderately susceptible) and Mycobacterium tuberculosis (only moderately susceptible). Most strains of Pseudomonas cepacia and some strains of Pseudomonas maltophilia are resistant to ciprofloxacin as are most anaerobic bacteria, including Bacteriodes fragilis and Clostridium difficile. The minimal bactericidal concentration (MBC) generally does not exceed the minimal inhibitory concentration (MIC) by more than a factor of 2. Resistance to ciprofloxacin in vitro usually develops slowly (multiple-step mutation). Ciprofloxacin does not cross-react with other antimicrobial agents such as beta-lactams or aminoglycosides; therefore, organisms resistant to these drugs may be susceptible to ciprofloxacin.
2018
30
CIPROFLOXACIN HYDROCHLORIDE
ciprofloxacin
Post-LOE
SMORAL · TABLET
[see Microbiology ( )].
plagueincluding pneumonicsepticemic plague+38 more
2018
30
DICLOFENAC SODIUM
diclofenac sodium
Post-LOE
OPHTHALMIC · SOLUTION/DROPS
CLINICAL PHARMACOLOGY Pharmacodynamics Diclofenac sodium is one of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins. Animal Studies Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure. Pharmacokinetics Results from a bioavailability study established that plasma levels of diclofenac following ocular instillation of two drops of Diclofenac sodium ophthalmic solution, 0.1% to each eye were below the limit of quantification (10 ng/mL) over a 4-hour period. This study suggests that limited, if any, systemic absorption occurs with Diclofenac sodium ophthalmic solution, 0.1%. Clinical Trials Postoperative Anti-Inflammatory Effects In two double-masked, controlled, efficacy studies of postoperative inflammation, a total of 206 cataract patients were treated with Diclofenac sodium ophthalmic solution, 0.1% and 103 patients were treated with vehicle placebo. Diclofenac sodium ophthalmic solution, 0.1% was favored over vehicle placebo over a 2-week period for the clinical assessments of inflammation as measured by anterior chamber cells and flare. In double-masked, controlled studies of corneal refractive surgery (radial keratotomy (RK) and laser photorefractive keratectomy (PRK)) patients were treated with Diclofenac sodium ophthalmic solution, 0.1% and/or vehicle placebo. The efficacy of Diclofenac sodium ophthalmic solution, 0.1% given before and shortly after surgery was favored over vehicle placebo during the 6-hour period following surgery for the clinical assessments of pain and photophobia. Patients were permitted to use a hydrogel soft contact lens with Diclofenac sodium ophthalmic solution, 0.1% for up to three days after PRK.
postoperative inflammation in patientsfor the temporary relief of painphotophobia in patients undergoing corneal refractive surgery
2015
30
FELODIPINE
felodipine
Post-LOE
SMORAL · TABLET, EXTENDED RELEASE
Calcium Channel Antagonists
hypertensionto lower blood pressureheart failure
2018
30
LAMOTRIGINE
lamotrigine extended-release
Post-LOE
ORAL · TABLET, EXTENDED RELEASE
Organic Cation Transporter 2 Inhibitors
2021
30
LETROZOLE
letrozole
Post-LOE
SMORAL · TABLET
Aromatase Inhibitors
2018
30
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride
Post-LOE
INJECTION · INJECTABLE
2022
30
LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride
Post-LOE
INJECTION · INJECTABLE
2022
30
MEMANTINE HYDROCHLORIDE
memantine hydrochloride
Post-LOE
ORAL · TABLET
N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer's disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer's disease.
moderate to severe dementia of the Alzheimer's type
2020
30
Open Jobs (1)
Interview Prep Quick Facts
Founded: 2023
Portfolio: 30 approved products
Top TAs: Neurology, Cardiovascular, Infectious Diseases
H-1B (2023): 1 approval
Open Roles: 1 active job
Portfolio Health
Pre-Launch1 (3%)
Peak1 (3%)
LOE Approaching5 (17%)
Post-LOE23 (77%)
30 total products
Therapeutic Area Focus
Neurology
4 marketed
Cardiovascular
2 marketed
Infectious Diseases
2 marketed
Nephrology
2 marketed
Oncology
2 marketed
Gastroenterology
1 marketed
Immunology
1 marketed
Respiratory
1 marketed
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub